» Articles » PMID: 22094060

Hydrophobic Statins Induce Autophagy and Cell Death in Human Rhabdomyosarcoma Cells by Depleting Geranylgeranyl Diphosphate

Overview
Journal Eur J Pharmacol
Specialty Pharmacology
Date 2011 Nov 19
PMID 22094060
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Statins are the most common type of medicine used to treat hypercholesterolemia; however, they are associated with a low incidence of myotoxicity such as myopathy and rhabdomyolysis. The mechanisms for the adverse effects remain to be fully elucidated for safer chronic use and drug development. The results of our earlier work suggested that hydrophobic statins induce autophagy in cultured human rhabdomyosarcoma A204 cells. In this study, we first confirmed the statin-induced autophagy by assessing other criteria, including induced expression of the autophagy-related genes, enhanced protein degradation of autophagy marker protein p62 and electron microscopic observation of induced formation of autophagosome. We next demonstrated that the extent of inhibition of HMG-CoA reductase in the cell is parallel with the ability of a statin to induce autophagy. Thus, the primary activity of statins causes autophagy in A204 cells. Considering the mechanism for the induction, we showed that statins induce autophagy by depleting cellular levels of geranylgeranyl diphosphate (GGPP) mostly through an unknown pathway that does not involve two major small G proteins, Rheb and Ras. Finally, we demonstrated that the ability of statins to induce autophagy parallels their toxicity to A204 cells and that both can be suppressed by GGPP.

Citing Articles

Synthetic inhibition of SREBP2 and the mevalonate pathway blocks rhabdomyosarcoma tumor growth in vitro and in vivo and promotes chemosensitization.

Codenotti S, Asperti M, Poli M, Lorenzi L, Pietrantoni A, Cassandri M Mol Metab. 2024; 92:102085.

PMID: 39706565 PMC: 11750561. DOI: 10.1016/j.molmet.2024.102085.


Statin-Sensitive Akt1/Src/Caveolin-1 Signaling Enhances Oxidative Stress Resistance in Rhabdomyosarcoma.

Codenotti S, Sandrini L, Mandracchia D, Lorenzi L, Corsetti G, Poli M Cancers (Basel). 2024; 16(5).

PMID: 38473215 PMC: 11154391. DOI: 10.3390/cancers16050853.


Targeted Mevalonate Pathway and Autophagy in Antitumor Immunotherapy.

Xing Z, Jiang X, Wu Y, Yu Z Curr Cancer Drug Targets. 2024; 24(9):890-909.

PMID: 38275055 DOI: 10.2174/0115680096273730231206054104.


Metabolic Disorder Therapeutics and their Effects on Memory.

Aggarwal P, Khan F, Banerjee S CNS Neurol Disord Drug Targets. 2023; 23(9):1061-1074.

PMID: 37921148 DOI: 10.2174/0118715273269329231013074613.


Dysregulation of cholesterol metabolism in cancer progression.

Liu X, Lv M, Zhang W, Zhan Q Oncogene. 2023; 42(45):3289-3302.

PMID: 37773204 DOI: 10.1038/s41388-023-02836-x.